The possibility of improving diagnosis of micrometastases from prostate cancer by further enhancing the detection of prostate-specific antigen-producing cells in circulation is being evaluated. We have developed a reverse transcriptase-PCR protocol with the desirable characteristics of low limit of detection, high specificity, reproducibility of response, and ease of performance. Among the procedural alterations that have contributed to these improvements are longer PCR primers, a twostep amplification cycle, and hot-start PCR. We have lowered the limit of detection to one LNCaP prostatecancer cell in 10 8 peripheral blood mononuclear cells, and samples of blood and bone marrow from healthy donors have yielded no false positives. Because PCR procedures frequently exhibit tube-to-tube variability, we have incorporated a set of internal and external controls into the protocol-a significant advance in assuring assay reliability. INDEXING TERMS: cancer • metastasis • peripheral blood mononuclear cells
Prostate cancer is an increasingly prevalent health problem among men worldwide. Although a complete cure can frequently be achieved through radical prostatectomy, ϳ20 -30% of the patients undergoing this procedure will relapse, even though their tumors had appeared to be clinically localized. Disease recurrence in this subset of patients may arise from the presence of prostate-cancer cells outside the prostate that were undetected at the time of surgery. Accurate staging of the disease when gross metastases are not evident is problematic because the techniques currently in use have poor detection limits for micrometastases. There is therefore an urgent need for improved methods of detecting disseminated prostate cancer.
Gene-amplification techniques, with their high sensitivity, can be used to address this need. Since 1987, reverse transcriptase-polymerase chain reaction (RT-PCR) methodology has been used to detect circulating cells shed by solid tumors, utilizing, e.g., tyrosinase for melanoma [1] ; tyrosine hydroxylase for neuroblastoma [2] ; ␣-fetoprotein for hepatoma [3] ; and cytokeratin for breast cancer [4] . 1 This broad spectrum demonstrates the diagnostic potential of the RT-PCR method. The premise of this approach is that the cells to be detected express mRNA that is not found in other cells within the environment being tested. For detecting prostate cells in circulation, the target transcripts of choice are currently prostatespecific antigen (PSA) and prostate-specific membrane antigen [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Despite the promise of this method, however, it is not yet clear whether RT-PCR will prove to be of clinical value in staging prostate cancer. Results to date are mixed [6 -27] . The efficiency of circulating tumor cells in causing metastasis is also controversial [28 -33] . Better methods and protocols, along with more-comprehensive studies with longer follow-up, are needed to answer these questions.
Here we report an enhanced RT-PCR protocol for detecting prostate cells in circulation by targeting PSA sequences. We have designed and evaluated endogenous and exogenous internal and external controls to ensure uniform performance of the tests. The detection limit of the protocol is ϳ1 PSA-positive LNCaP cell per 10 8 peripheral blood mononuclear cells (PBMC), or 5 copies of PSA cDNA, with no signal from negative-control samples.
Materials and Methods samples
Cell culture. The human prostate cancer cell line LNCaP was obtained from the American Type Culture Collection (Rockville, MD). Cells were grown in RPMI 1640 plus 100 mL/L fetal bovine serum.
Collection of blood samples and isolation of mononuclear cells.
Samples of venous blood (8 mL) were drawn into Vacutainer Tube CPT cell-preparation tubes (Becton Dickinson, Franklin Lakes, NJ) and processed within 2 h. After the samples were centrifuged at 1500 -1800g for 30 min at room temperature, the resulting PBMC layers were gently resuspended in plasma and transferred to 50-mL tubes. The volume was brought to 40 mL with Dulbecco's phosphate-buffered saline, and 10-L aliquots were removed and diluted with 40 L of 30 mL/L acetic acid for cell counts. The remaining cells were centrifuged at 300g for 20 min at 4°C and the cell pellets were resuspended in STAT-60 (Tel-Test "B", Friendswood, TX) for RNA isolation.
Collection of bone marrow samples and isolation of mononuclear cells.
Bone marrow samples (10 mL) were drawn into 20-mL syringes containing 10 mL of 60 g/L sodium citrate solution (Pharmaceutical Services, University of Washington, Seattle, WA). The mixtures were transferred to 50-mL tubes, underlaid with 15 mL of Histopaque-1077 (Sigma, St. Louis, MO), and centrifuged at 400g for 30 min at room temperature. The resulting opaque layers containing the mononuclear cells were then transferred to new tubes and brought to 40 mL volume with phosphate-buffered saline. The cells were isolated for counting as described for blood samples. We processed all of the isolated PBMC for RNA extraction to maximize the chance of detecting prostate cells.
procedures RNA isolation. Total RNA was isolated from PBMC by using STAT-60 Total RNA Isolation Reagent (Tel-Test "B") according to the manufacturer's recommendations, except that we used 1 mL of STAT-60 per 5 ϫ 10 6 PBMC, rather than 1 mL per 10 ϫ 10 6 PBMC. The isolated RNA was dissolved in 15 L of "Molecular-Biology-grade" water (5prime-3prime, Boulder, CO) in siliconized, RNase-and DNase-free microcentrifuge tubes. The RNA concentration was determined by measuring absorbance at 260 nm. A 5-g aliquot of RNA was used for reverse transcription (RT) and the remainder was stored under ethanol at Ϫ80°C.
Reverse transcription.
RT was performed in a volume of 20 L, as follows: 5 g of total RNA and 1 L (0.05 g) of Random Hexamers (Perkin-Elmer, Branchburg, NJ) were brought up to 10 L with Molecular-Biology-grade water, heated to 70°C for 10 min, and then cooled immediately on ice. A master mixture was prepared, 10 L for each sample, as follows: 4 L of 5ϫ First Strand Buffer (i.e., 250 mmol/L Tris-HCl, pH 8.3 at room temperature, 375 mmol/L KCl, and 15 mmol/L MgCl 2 ); 2 L of 0.1 mol/L dithiothreitol; 1 L of a mixture of dATP, dGTP, dCTP, and dTTP, each at 2.5 mmol/L; 1 L of RNase Inhibitor (10 units; Perkin-Elmer); 1 L of reverse transcriptase (200 units, Superscript II Reverse Transcriptase; Gibco-BRL Life Technologies, Grand Island, MD), and 1 L of H 2 O. The master mixture was added to each sample tube (containing RNA and primers) and heated for 5 min at 25°C, followed by 1 h at 42°C. The reverse transcriptase was deactivated by heating at 99°C for 5 min. To ensure specificity of the MIC PCR, we used hot-start conditions: For each sample we mixed 0.5 L of Taq DNA Polymerase (2.5 units; Gibco-BRL) with 0.5 L of TAQSTART antibody (Clontech Labs., Palo Alto, CA) and incubated this for 5 min at room temperature before adding it to the master mixture. Cycling conditions (Omnigene Thermal Cycler, Hybaid, Middlesex, UK) were: 80°C for 3 min, 1 cycle; 94°C for 5 s and 69°C for 1 min, 25 cycles; and 72°C for 7 min, 1 cycle. Reaction products were analyzed by electrophoresis in 1.5% agarose gels with 50 mmol/L Tris-borate buffer containing 1 mmol/L EDTA, and were stained with ethidium bromide.
PSA PCR. The PSA oligonucleotides (Integrated DNA Technologies) were chosen from regions exhibiting high sequence divergence between PSA cDNA and the closely related human glandular kallikrein cDNA (hK2; GenBank M18157), which also is expressed by prostate tissue.
5Ј PSA primer TTGTGGCCTCTCGTGGCAGGGCAGT 3Ј PSA primer TGGTCACCTTCTGAGGGTGAACTTGC PSA cDNA and hK2 cDNA differ at 10 positions within the sequence of the 5Ј primer and 9 positions within the 3Ј primer. Because the primer sequences are from different exons of PSA mRNA (5Ј PSA, exon 2; 3Ј PSA, exon 4), the researcher can easily determine the presence of genomic DNA contaminants, which would yield much larger products. The 460-bp PCR fragment obtained with these primers has the same sequence as positions 110 -569 of PSA cDNA (GenBank M21895).
Specificity of the primers was verified with the GCG UNIX program (see above). PCR was performed in 50-L volumes as described for MIC PCR, except that 5 L of prepared cDNA and 5 pmol of each primer were used and the cycling conditions were 80°C for 3 min, 1 cycle; 94°C for 5 s; 69°C for 1 min, 40 cycles; 72°C per 7 min, 1 cycle.
Restriction enzyme digestion. To 13 L of the PSA PCR samples were added 1.5 L of 10ϫ ClaI enzyme reaction buffer (500 mmol/L Tris-HCl, pH 8, and 100 mmol/L MgCl 2 ) and 0.5 L of ClaI enzyme (both from Gibco-BRL). The reaction mixture was incubated for 1 h at 37°C, and the products were analyzed by agarose gel electrophoresis.
Cloning and sequencing PCR products. PSA PCR products were cloned directly with use of a TA Cloning Kit (Invitrogen, San Diego, CA). Plasmids were transformed into electro-competent Escherichia coli JM109, purified with a Wizard Plasmid Preparation Kit (Promega, Madison, WI), screened by restriction analysis, and sequenced.
determination of detection limit
The detection limit of our protocol was tested in three ways. First, we determined the detection limit of the PCR step by performing PCR with serial dilutions of PSA cDNA cloned into pGEM-3Z (gift ofÅke Lundwall, Malmo, Sweden), 0 to 160 copies per reaction. Second, we added LNCaP cells total RNA or LNCaP cells to total PBMC RNA or PBMC, respectively, at a ratio of 1 LNCaP cell (or RNA equivalent) per 10 4 , 10 5 , 10 6 , 10 7 , or 10 8 PBMC (or RNA equivalent) and assayed by RT-PCR to determine how few cells could be detected. Third, to test the detection limit of the entire procedure, we added 2-20 LNCaP cells to 8 mL of PSA-negative blood from female donors. Confluent LNCaP cells were harvested, washed, and counted with a hematocytometer; we then diluted 10 6 cells resuspended in 1 mL of RPMI 1640 in 10-fold serial dilutions. For the 10 5 /mL dilutions of LNCaP cells, the cells were counted by standard procedures with a hematocytometer; for lower dilutions (10 4 , 10 3 , and 10 2 /mL), we counted the cells in 10 or 20 L of the cell suspension pipetted onto a microscope slide with a grid. We then pipetted 20 -200-L aliquots of the 10 2 /mL LNCaP cell preparation (containing 2, 5, or 20 cells) into PSA-negative blood samples and processed the cells as described above. The expected frequency of occurrence of various numbers of cells at extreme dilutions was calculated according to the binomial distribution since the number of cells observed is very small relative to the number of cells in the pool (1 ϫ 10 7 to 2 ϫ 10 7 ).
exogenous internal competitive dna control (ic-psa)
Construction. PSA cDNA excised by EcoRI from pGEM-3Z was recloned into the unique EcoRI site of the plasmid pLOT731 (unlike pGEM-3Z, pLOT731 contains no SacI site). The resulting plasmid was linearized at position 420 of the PSA cDNA by SacI digestion. After treatment with phosphatase (Boehringer Mannheim, Indianapolis, IN), an unrelated PCR fragment 258 bp long was inserted into the SacI site. The insert was prepared by PCR amplification of FAU cDNA positions 164 -416 (GenBank X65923) with primers containing SacI restriction sites. This PCRamplified fragment was digested with SacI, gel-purified, and ligated into the SacI-digested pLOT731 PSA clone. The plasmid was transformed into E. coli JM109. Bacterial colonies containing the desired extended PSA sequences were identified by PCR. Desired colonies yielded a PCR band of 720 bp, representing IC-PSA. This IC-PSA cDNA was excised with EcoRI and cloned back into pGEM-3Z for in vitro transcription.
PCR performance evaluation. Plasmids (pGEM-3Z) containing either PSA cDNA or IC-PSA cDNA were serially diluted and combined for use in PCR. We used equal amounts of each cDNA in the range 0.00001-1 pg (5-500 000 copies) of each plasmid DNA. In addition, we used three different amounts of IC-PSA plasmid DNA (0.0001, 0.001, and 0.01 pg, equivalent to 50, 500, and 5000 copies, respectively) in combination with 0.00001-1 pg (5-500 000 copies) of PSA cDNA/pGEM-3Z.
In vitro RNA synthesis. IC-PSA cDNA in pGEM-3Z was used for RNA synthesis. The IC-PSA cDNA orientation in pGEM-3Z was determined by digestion with BamHI and SacI. An SP6 Megacript Kit (Ambion, Austin, CA) was used according to the manufacturer's recommendations to synthesize the exogenous internal competitive IC-PSA RNA. The plasmid was linearized at position 635 of the PSA sequence with ApaI; the resulting transcript was ϳ780 bp long. The RNA was used in RT-PCR to verify its identity. Identical reactions, but with reverse transcriptase omitted, were used to monitor contamination by plasmidderived IC-PSA cDNA.
RT-PCR performance evaluation. Various concentrations of IC-PSA RNA were added to 5 g of PSA-negative PBMC RNA that had been adulterated with 5 ϫ 10 Ϫ7 g of RNA Clinical Chemistry 43, No. 3, 1997 from LNCaP cells. These mixtures were then subjected to RT-PCR as described above.
Results

rt-pcr performance evaluated with dilutions of lncap cells
To monitor the specificity of the RT-PCR protocol for the PSA message, we used PSA-positive LNCaP cells. Confluent cells were harvested, and the RNA was extracted. RT was performed with 0.2 g of RNA from LNCaP cells, and PCRs for MIC and PSA were analyzed, yielding the expected 550-bp product from the MIC message and the 460-bp product from the PSA message. ClaI digestion of the PSA PCR product yielded two fragments, 220 and 240 bp (the hK2 gene does not have this restriction site, so the amplification product from hK2 would be unaffected by ClaI digestion). The PCR fragment from LNCaP cells was cloned and its identity confirmed by DNA sequencing.
To determine the detection limit of the optimized PCR protocol, we performed PCR on serial dilutions of pGEM-3Z with PSA cDNA, yielding 0 -160 copies of plasmid per reaction. Results are shown in Fig. 1 . Specificity of the primers for PSA was checked by PCR with an hK2-containing plasmid (gift of D. Tindall, Rochester, NY); no band was observed, even with high concentrations of hK2 cDNA (data not shown).
For evaluating and optimizing the RT portion of the procedure, we performed RT with serial dilutions of LNCaP RNA added to PBMC RNA to yield ratios of 1 prostate cancer cell to 10 4 , 10 5 , 10 6 , 10 7 , or 10 8 PBMC. We tested the use of 1, 2, or 5 g of RNA per reaction and 2, 3, and 5 L of RT product per PCR. The conditions exhibiting the lowest limit of detection and best reproducibility for detection of the PSA message were 5 g of RNA per RT reaction and 5 L of RT product per PCR. PCR with MIC primers (the endogenous external control) was used as a positive control for assessing RT performance and the presence of amplifiable messages. Using these conditions, we could detect 1 LNCaP cell per 10 8 PBMC, as shown in Fig. 2 . We obtained a positive signal from 1 LNCaP cell in a background of 10 8 PBMC in five out of five experiments performed with various LNCaP-and PBMC-RNA preparations over ϳ6 months.
We optimized the conditions for RNA extraction by adding dilutions of LNCaP cells directly into PBMC in the same ratios as above and extracting these mixtures. We found that following the manufacturer's recommendation to use 1 mL of STAT-60 per 10 ϫ 10 6 cells resulted in persistent DNA contamination, whereas using 1 mL of STAT-60 per 5 ϫ 10 6 cells alleviated the problem. RT-PCR was performed as described above. The detection limit of this cell-addition procedure was also 1 LNCaP cell per 10 8 PBMC (data not shown).
The limit of detection for the whole method depends on sample collection, blood handling, isolation of cells, and RNA extraction, as well as the RT-PCR procedure itself. For example, in our experience, blood collection into CPT tubes is superior to Ficoll methods for isolation of PBMC and circulating prostate cells. Final testing of the whole procedure was performed with 8-mL samples of blood supplemented directly with dilutions of LNCaP cells in RPMI 1640; the desired numbers of cells were added in volumes of at least 20 L to CPT tubes containing blood. The average number of cells observed in 10 L of a theoretical dilution of 10 4 cells per 1 mL was 98.75 Ϯ 10.62. We repeated these experiments over ϳ1 year with different preparations of LNCaP cells to establish our limit of detection, i.e., 2 LNCaP cells in 8 mL of peripheral blood ( Fig. 3 ). At this high dilution, the tube-to-tube variation in cell content is large relative to the mean; therefore, we used the binomial distribution, which showed that ϳ59.4% of the tubes would be expected to have at least 2 cells, while 13.5% would be expected to have none. To ascertain whether the actual cell delivery matched theory, we performed cell counts with cell dilutions representing 10 5 , 10 4 , 10 3 , and 10 2 LNCaP cells per milliliter. At a nominal dilution of 2 cells per 20 L (100/mL), the counts followed a gaussian distribution and yielded an average of 1.51 Ϯ 0.99 cells per aliquot (n ϭ 37). In particular, whereas the theoretical expectation was that 59.4% of the samples would contain 2 or more cells, the experimental value was 51.4%. A review of 12 RT-PCR experiments performed with the goal of adding 2 LNCaP cells to 8 mL of blood showed that 7 (58.3%) of the experiments yielded the PSA PCR product-in close agreement with the theoretical expectation that 59.4% of the supplemented blood samples would contain 2 or more cells.
Samples of peripheral blood (n ϭ 40) and bone marrow (n ϭ 30) from negative donors (females or young males) were used as a negative controls. None of the samples exhibited the 460-bp band for PSA mRNA. Preliminary data obtained from clinical trials by this procedure were presented at the 91st Annual American Urological Association Meeting [22, 23] .
evaluation of controls
We constructed the IC-PSA cDNA in pGEM-3Z for use in control procedures to evaluate RT-PCR performance. The IC-PSA plasmid contains a PSA cDNA sequence into which an unrelated 258-bp sequence has been inserted, and the IC-PSA cDNA can be amplified by the same primers as the normal PSA cDNA sequence. We performed four different experiments to test for simultaneous detection of the two cDNAs. First, we amplified equimolar mixtures of PSA cDNA/pGEM-3Z and IC-PSA cDNA/pGEM-3Z in the range 0 -500 000 copies (Fig. 4) .
Electrophoresis on 1.5% agarose gels easily discriminated the signals from these two sources. PSA cDNA yielded the 460-bp product, whereas the IC-PSA cDNA yielded a 720-bp product.
Second, because the amount of PSA message in clinical samples may vary, we tested the effect of three quantities of IC-PSA cDNA/pGEM-3Z (0.0001, 0.001, and 0.01 pg, or 50, 500, and 5000 copies) on PCR performance with PSA cDNA/pGEM-3Z in the range 0.0001-1 pg, or 5-500 000 copies. Because the two amplifications are competitive, the ratio of quantities within which both signals can be detected is limited. Within a factor of 10 in either direction, both bands were detected; at ratios outside this range, however, the more numerous species dominated and the other species was not observed. For example, Fig The quantity of PSA cDNA/pGEM-3Z used varied from 1 to 0.00001 pg (lanes 2-11, respectively), i.e., 500 000, 50 000, 15 000, 5000, 1500, 500, 150, 50, 15, and 5 copies. Lane 1 shows the 100-bp DNA ladder.
illustrates the use of 0.0001 pg (50 copies) of IC-PSA plasmid with PSA plasmid quantities of 0.00001-1 pg (5-500 000 copies). Under these conditions we could detect both IC-PSA cDNA and PSA cDNA in the lowest range in which the PSA cDNA itself is detected (0.00001 pg or 5 copies of PSA cDNA/pGEM-3Z). Figure 6 depicts the use of the IC-PSA control in PCR with clinical samples. Six clinical samples were examined with and without the IC-PSA control. The 720-bp band in the control lanes for samples 2, 3, and 4 indicates a proper performance of PCR, and these samples are clearly identified as true-negative samples. For sample 5, no amplification product was detected in either lane (lanes 5 and 5A), indicating that this sample is not a negative sample but rather a case of PCR failure. Another sample from this patient must be examined.
To explore the possibility of using IC-PSA at the RNA level to control for performance of RT, we prepared IC-PSA RNA by in vitro transcription. The RNA species obtained was ϳ780 nucleotides, yielding a DNA fragment of 720 bp by RT-PCR. A control experiment omitting the reverse transcriptase did not yield the 720-bp band. To check the recovery of IC-PSA RNA, we added various amounts of the RNA into aliquots of PBMC that had been adulterated with LNCaP cells, 1:10 7 . The signal from the IC-PSA RNA was detected when the IC-PSA RNA was present at 0.01-10 pg, whereas both IC-PSA and PSA signals were detected for IC-PSA RNA at 0.01-1 pg (Fig.  7) . However, because we found that the detection limit of IC-PSA RNA was highly variable, we adopted the approach of using an endogenous, external control (MIC) for RT performance and RNA integrity; this control procedure yields an extremely low rate of false negatives.
An additional control procedure is used only with PSA cDNA-positive samples. The product is digested by the restriction enzyme ClaI, which digests the product of PSA cDNA amplification to yield bands of 220 and 240 bp. Fig.  8 shows the results of ClaI digestion of the PSA and IC-PSA PCR products, as well as a mixture of the two that had been mixed with undigested PSA cDNA after digestion of the pair of products to demonstrate that the undigested band can be easily distinguished from all of the reaction products.
Discussion
Metastases account for the majority of cancer deaths. However, the ability of current staging techniques to detect micrometastases is insufficient to support optimal treatment choices. Investigators hope that detection of prostate cells in circulation, even in very low quantities, may provide a new and highly sensitive staging tool for prostate cancer. In 1974, Liotta et al. demonstrated in an animal model that as few as 4 circulating cells appeared to be sufficient for hematogenous dissemination of tumor cells [33] . In 1992, Hamdy et al. reported the presence of cells producing PSA in the circulation of some patients with proven prostate cancer metastases [5] . Because PSA is produced almost exclusively by prostate epithelial cells [34 -38] , the presence of PSA-positive cells in circulation clearly indicates an abnormal condition, and a strong correlation between the appearance of prostate cells in circulation and the advent of metastasis might be expected. Although one group has reported a correlation between the presence of PSA message-positive cells in peripheral blood and recurrent disease after surgery [8, 15, 19, 26] , other groups have reported inconclusive results [9 -14, 16 -18, 20 -25] . The implications of the presence of prostate cells in circulation are therefore not entirely clear, and a great deal of work remains to be done. Identification and widespread adoption of the best methods for detecting these circulating cells are needed, so that more systematic studies with long-term follow-up may be undertaken and proper conclusions can be drawn.
Because of its sensitivity and selectivity, RT-PCR offers significant improvements in the detection of circulating prostate epithelial cells. Moreover, the detection limit of RT-PCR is better than that of any other methods in current use, e.g., flow cytometry or immunohistochemistry. There is therefore considerable interest in using RT-PCR to detect prostate cells in peripheral blood and bone marrow samples from patients with prostate cancer [5-15, 19 -32] . The bone marrow is of particular interest because of the tendency of prostate cancer to metastasize to bone. In the case of breast cancer, which resembles prostate cancer in being hormone-responsive, there is a documented relation between the presence of breast cancer cells in bone marrow and metastasis [39 -42] . Although RT-PCR alone cannot determine whether the PSA cDNA-positive cells detected have malignant properties, correlations with pathology data [6] suggest a possible link between the presence of such cells in circulation and occult metastatic spread of the prostate cancer. Before 1996, the detection limits published for RT-PCR of PSA mRNA did not surpass 1 LNCaP cell in a background of 10 6 negative cells, as determined by use of a combination of RT-PCR with Southern transfer [6] , signal amplification by digoxigenin [8] , biotin-streptavidin systems in post-PCR ELISA [14] , or nested RT-PCR [7] . Recent abstracts have reported detection of 1 LNCaP cell in 10 7 PBMC (Marakovskiy A, Halpert G, Stein B, Hixson DC. Improved RT-PCR detection of circulating tumor cells in patients with prostate cancer, Abstract at 87th American Association for Cancer Research Annual Meeting, 1996) and 10 8 PBMC [16, 17] . At the 91th American Urological Association Annual Meeting, O'Hara et al. reported (unpublished data) that they detected PSA signal in control samples-7 of 90 men (7.8%), 4 of 44 women (9.1%), and 9 of 54 (16.7%) patients with biopsy-proven benign prostatic hyperplasia-by using the procedure described elsewhere at that meeting [16, 17] . They hypothesized that basal amounts of PSA mRNA expression might be responsible for these false positives. However, the agreement between this "falsepositive" RT-PCR rate in biopsy-negative patients (16.7%) and the known false-negative rate of biopsies (15-20%) is highly suggestive. That is, these results may not be false positives but rather indicate cases in which RT-PCR has surpassed biopsy as a means of early diagnosis of prostate cancer. Follow-up studies on the patients giving falsepositive results in the RT-PCR assay are desirable.
With clinical utility in mind, we set out to develop an RT-PCR protocol that would be highly sensitive and easy to use. Our protocol has a detection limit of 1 LNCaP cell in 10 8 negative cells, with no false-positive results. Using oligonucleotides 25 and 26 bases long enables us to use a faster, two-step PCR, and hot-start conditions contribute to the high specificity of amplification.
Use of RT-PCR in the clinical setting requires proper controls to assure the validity of results. There are two ways of classifying RT-PCR controls: endogenous or exogenous, and internal or external; in our protocols, the control procedures to be performed with every run are an endogenous external control and an exogenous internal control. The first control is endogenous because it involves amplification of MIC, a species naturally present in the sample; it is external because the amplification is performed in a different reaction vessel. The second control involves addition of the artificially createdexogenous-IC-PSA cDNA to the reaction tube in which the PSA PCR is taking place; this is therefore an internal control procedure for the reaction. The combination of these two procedures ensures the integrity of both the sample and the amplification procedures and virtually eliminates the effect of tube-to-tube variability on the results of the test. In addition to these controls, a detection-limit control containing ϳ5 copies of PSA cDNA is also run side-by-side with the target samples, and a reaction without cDNA (water control) is run to monitor reagent contamination. Finally, restriction analysis by Cla I is used to confirm the identity of the product in PSA cDNA-positive samples.
The experiments with IC-PSA DNA showed that one could detect both target and internal control sequences when the concentrations of the two did not differ by more than 10-fold. Outside this range, the more-numerous species dominated the reaction and prevented detection of the other species. We therefore decided that 0.0001 pg (50 copies) of the IC-PSA plasmid was the optimal amount to add to the PCR mixture for use with clinical samples (Fig. 6 ). This permits control of PSA PCR performance at the lowest limit of detection. Higher concentrations of target PSA cDNA dominate the reaction, preventing efficient amplification of IC-PSA cDNA. However, in the lower limit of detection range, the presence of the 720-bp IC-PSA band verifies the PCR performance and greatly reduces the probability that an apparent negative result is in fact a false negative.
Although IC-PSA was constructed for use as a control for both the DNA and RNA aspects of the reaction, we found that RT with the IC-PSA transcript was not sufficiently reproducible for use as a clinical control, possibly Clinical Chemistry 43, No. 3, 1997 because of degradation of uncapped RNA, or loss through interaction with the container's surface at the low concentrations needed for this reaction. Trouble-shooting this control procedure will require additional effort. We therefore settled on the MIC message as a noncompetitive endogenous control for the RT phase of the reaction. The message transcribed from this housekeeping gene is known to be present at approximately constant amounts in all samples we are likely to encounter [43] . This type of external control also provides information about the integrity of the RNA preparation. The choice of a gene for use as the endogenous external control is an important issue: The commonly used housekeeping genes glyceraldehyde-3-phosphate dehydrogenase and ␤-actin both have the disadvantage that matching processed pseudogenes are known to exist in the human genome. If primers can anneal to a pseudogene, PCR can potentially amplify genomic DNA contamination in addition to the target cDNA, and the two products would be indistinguishable in size. This is a serious problem, because amplification of the pseudogene present in DNA contamination of the RNA preparation would lead to a false assurance that the RT was successful, when in fact the RT may have failed. One must therefore check for the presence of a pseudogene before settling on a particular housekeeping gene to use as a positive RT control.
To eliminate false-positive results, we further tested each PSA-positive sample by digestion with ClaI. Digestion of the 460-bp PSA product by this enzyme yields bands of 220 and 240 bp. The hK2 product, on the other hand, is not digested by this enzyme. This additional step allows us to distinguish a true PSA-amplification event from artifacts caused by mispriming of messages of similar size-and presents a simple alternative to the use of Southern transfer or DNA sequencing procedures to confirm the identity of the amplification products. In the 1100 samples we have thus far examined with this procedure, Ͻ1% have yielded 460-bp products that were not digestible by ClaI. In samples that do not exhibit the 460-bp band, however, we have occasionally seen a band of ϳ430 -450 bp that is not digestible by ClaI. Careful examination of electrophoresis results is therefore necessary. Despite the very low frequency of occurrence of false positives, we have performed ClaI digestion for all samples exhibiting bands of a size similar to that of the expected PSA product. The IC-PSA cDNA does not interfere with the interpretation of the digestion result, and in fact represents a positive control for ClaI performance (Fig. 8) .
Improvements in RT-PCR procedures leading to a lower detection limit are of potential clinical significance for at least two reasons. First, whereas a typical blood aliquot provides ϳ10 7 cells, a bone-marrow sample can easily provide 10 8 cells, which improves the desired detection limit by an order of magnitude. Second, the procedures described rely on the cell-line LNCaP as a source of PSA-positive cells; however, prostate-cancer cells express variable amounts of PSA mRNA [44] . This is not to say that there is no lower bound to the detection limit desired. Smith et al. have detected PSA message in many cell lines that are not of prostate origin, as well as in PBMC of control subjects [11] . Such ultrasensitive methods as the ones they have developed are not suitable for prognostic procedures in prostate cancer because a positive result, although it may in fact indicate the presence of PSA messages outside the prostate, has little or no pathological significance [45] . In developing diagnostic assays incorporating RT-PCR, one must strike a balance between specificity and detection limit.
In our view, attempts to quantify the PSA-PCR results would complicate the procedure without adding benefits. True quantification of results would require a very detailed examination of the internal RNA controls; because of the wide variation in amounts of PSA mRNA present in prostate cancer cells, however, it is not clear that any improvements in clinical significance would result. Even if we could quantify precisely the number of PSA mRNA molecules in the sample, we would still not know whether the number obtained indicated few cells, each containing many PSA messages, or many cells that contained few messages.
Given that the degree of correlation between the presence of PSA-positive cells in blood or bone marrow and patient prognosis is not yet known, it is too early to assess the significance of the improved detection limit and specificity obtained with these procedures. Clinical trials with the improved RT-PCR protocol are currently underway, designed to evaluate the usefulness of PSA RT-PCR in peripheral blood samples and bone marrow specimens in staging prostate cancer before radical prostatectomy and as a prognostic indicator after prostatectomy [22, 23] . After more-extensive evaluation with clinical samples, we expect to include IC-PSA as an internal control in the next series of clinical trials.
